SCHEMBL7429649

SCHEMBL7429649

Nc1ccc(N)c2c1C(=O)NC2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 3/20 0.55
ADORA2A P29274 3/20 0.44
CSNK1A1 P48729 3/20 0.44
MAOA P21397 2/20 0.44
CSNK1D P48730 2/20 0.44
CSNK1G1 Q9HCP0 2/20 0.44
PIM1 P11309 2/20 0.44
FGR P09769 1/20 0.44
DYRK1A Q13627 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
POLB P06746 4/20 0.43
MAPT P10636 4/20 0.43
BLM P54132 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
PARP1 P09874 3/20 0.43
APEX1 P27695 2/20 0.43
RECQL P46063 2/20 0.43
CASP7 P55210 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290348 0.88 THRB (0.50) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL31717008 0.86 MEN1 (0.50) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL11152933 0.86 ADORA2A (0.50) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL3039233 0.86 MEN1 (0.50) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL18170525 0.81 MAOA (0.45) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL11766846 0.79 TDP1 (0.44) THRBMEN1KMT2APOLBMAPT
SCHEMBL767501 0.78 PARP1 (0.50) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL221618 0.76 PARP1 (0.53) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL29372946 0.76 PARP1 (0.53) THRBADORA2ACSNK1A1MAOACSNK1D
SCHEMBL31717058 0.75 CTRC (0.39) THRBMEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
WO-2020117832-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS (US) 2020-06-11 WO disclosed
WO-2020117832-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS (US) 2020-06-11 WO disclosed
US-20020128208-A1 Nonpeptide agonists and antagonists of vasopressin receptors EMORY UNIVERSITY 2002-09-12 US disclosed
WO-2002047679-A2 NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS EMORY UNIVERSITY (US) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128208-A1 Nonpeptide agonists and antagonists of vasopressin receptors AVPR1A, AVPR2, AVPR1B THRB 209/4885ADORA2A 142/4885CSNK1A1 1509/4885
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION BLVRB, TFPI, ETFB THRB 2894/4885ADORA2A 4798/4885CSNK1A1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.